MiR-129-5p is down-regulated and involved in the growth, apoptosis and migration of medullary thyroid carcinoma cells through targeting RET

FEBS Letters

Volumn 588, Issue 9, 2014, Pages 1644-1651

  Duan, Lijun ^a   Hao, Xiaofang ^b   Liu, Zhiyong ^b   Zhang, Yang ^a   Zhang, Guangling ^b  

^a TIANJIN FIRST CENTRAL HOSPITAL   (China)

^b HEBEI UNITED UNIVERSITY   (China)

Author keywords

Cell apoptosis; Cell growth; Cell migration; Medullary thyroid carcinoma; MiR 129 5p; REarranged during Transfection proto oncogene

Indexed keywords

MICRORNA; MICRORNA 129 5P; PROTEIN KINASE B; UNCLASSIFIED DRUG;

3' UNTRANSLATED REGION; APOPTOSIS; ARTICLE; CANCER INHIBITION; CARCINOGENESIS; CELL GROWTH; CELL MIGRATION; CELL VIABILITY; CONTROLLED STUDY; DOWN REGULATION; ENZYME PHOSPHORYLATION; GENE MUTATION; GENE TARGETING; HUMAN; HUMAN CELL; PHENOTYPE; PRIORITY JOURNAL; PROTO ONCOGENE; THYROID MEDULLARY CARCINOMA;

CELL APOPTOSIS; CELL GROWTH; CELL MIGRATION; MEDULLARY THYROID CARCINOMA; MIR-129-5P; REARRANGED DURING TRANSFECTION PROTO-ONCOGENE;

3' UNTRANSLATED REGIONS; ANIMALS; APOPTOSIS; BASE SEQUENCE; BINDING SITES; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; CELL SURVIVAL; DOWN-REGULATION; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MICE; MICE, INBRED BALB C; MICE, NUDE; MICRORNAS; NEOPLASM TRANSPLANTATION; PROTO-ONCOGENE PROTEINS C-RET; RNA INTERFERENCE; THYROID NEOPLASMS; TUMOR BURDEN;

EID: 84899634089     PISSN: 00145793     EISSN: 18733468     Source Type: Journal    
DOI: 10.1016/j.febslet.2014.03.002     Document Type: Article

References (20)

1. F. Pacini, M.G. Castagna, L. Brilli, and G. Pentheroudakis Thyroid cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up Ann. Oncol. 23 Suppl. 7 2012 vii110 vii119
2. S. Leboulleux, E. Baudin, J.P. Travagli, and M. Schlumberger Medullary thyroid carcinoma Clin. Endocrinol. (Oxf) 61 2004 299 310
3. L. Santarpia, L. Ye, and R.F. Gagel Beyond RET: potential therapeutic approaches for advanced and metastatic medullary thyroid carcinoma J. Intern. Med. 266 2009 99 113
4. M. Drosten, and B.M. Putzer Mechanisms of disease: cancer targeting and the impact of oncogenic RET for medullary thyroid carcinoma therapy Nat. Clin. Pract. Oncol. 3 2006 564 574
5. L. Ye, L. Santarpia, and R.F. Gagel The evolving field of tyrosine kinase inhibitors in the treatment of endocrine tumors Endocr. Rev. 31 2010 578 599
6. H. Glen, S. Mason, H. Patel, K. Macleod, and V.G. Brunton E7080, a multi-targeted tyrosine kinase inhibitor suppresses tumor cell migration and invasion BMC Cancer 11 2011 309
7. R.C. Friedman, K.K. Farh, C.B. Burge, and D.P. Bartel Most mammalian mRNAs are conserved targets of microRNAs Genome Res. 19 2009 92 105
8. F. Marini, E. Luzi, and M.L. Brandi MicroRNA role in thyroid cancer development J. Thyroid Res. 2011 2011 407123
9. X. Li, A.B. Abdel-Mageed, D. Mondal, and E. Kandil MicroRNA expression profiles in differentiated thyroid cancer, a review Int. J. Clin. Exp. Med. 6 2013 74 80
10. P. Pallante, R. Visone, M. Ferracin, A. Ferraro, M.T. Berlingieri, G. Troncone, G. Chiappetta, C.G. Liu, M. Santoro, M. Negrini, C.M. Croce, and A. Fusco MicroRNA deregulation in human thyroid papillary carcinomas Endocr. Relat. Cancer 13 2006 497 508
11. R. Visone, L. Russo, P. Pallante, I. De Martino, A. Ferraro, V. Leone, E. Borbone, F. Petrocca, H. Alder, C.M. Croce, and A. Fusco MicroRNAs (miR)-221 and miR-222, both overexpressed in human thyroid papillary carcinomas, regulate p27Kip1 protein levels and cell cycle Endocr. Relat. Cancer 14 2007 791 798
12. J. Hudson, E. Duncavage, A. Tamburrino, P. Salerno, L. Xi, M. Raffeld, J. Moley, and R.D. Chernock Overexpression of miR-10a and miR-375 and downregulation of YAP1 in medullary thyroid carcinoma Exp. Mol. Pathol. 95 2013 62 67
13. C. Mian, G. Pennelli, M. Fassan, M. Balistreri, S. Barollo, E. Cavedon, F. Galuppini, M. Pizzi, F. Vianello, M.R. Pelizzo, M.E. Girelli, M. Rugge, and G. Opocher MicroRNA profiles in familial and sporadic medullary thyroid carcinoma: preliminary relationships with RET status and outcome Thyroid 22 2012 890 896
14. P. Brest, S. Lassalle, V. Hofman, O. Bordone, V. Gavric Tanga, C. Bonnetaud, C. Moreilhon, G. Rios, J. Santini, P. Barbry, C. Svanborg, B. Mograbi, B. Mari, and P. Hofman MiR-129-5p is required for histone deacetylase inhibitor-induced cell death in thyroid cancer cells Endocr. Relat. Cancer 18 2011 711 719
15. R. Ogawa, H. Ishiguro, Y. Kuwabara, M. Kimura, A. Mitsui, T. Katada, K. Harata, T. Tanaka, and Y. Fujii Expression profiling of micro-RNAs in human esophageal squamous cell carcinoma using RT-PCR Med. Mol. Morphol. 42 2009 102 109
16. X. Yu, H. Song, T. Xia, S. Han, B. Xiao, L. Luo, Y. Xi, and J. Guo Growth inhibitory effects of three miR-129 family members on gastric cancer Gene 532 2013 87 93
17. M. Karaayvaz, H. Zhai, and J. Ju MiR-129 promotes apoptosis and enhances chemosensitivity to 5-fluorouracil in colorectal cancer Cell Death Dis. 4 2013 e659
18. Y. Liu, Y. Hei, Q. Shu, J. Dong, Y. Gao, H. Fu, X. Zheng, and G. Yang VCP/p97, down-regulated by microRNA-129-5p, could regulate the progression of hepatocellular carcinoma PLoS ONE 7 2012 e35800
19. M. Li, L. Tian, L. Wang, H. Yao, J. Zhang, J. Lu, Y. Sun, X. Gao, H. Xiao, and M. Liu Down-regulation of miR-129-5p inhibits growth and induces apoptosis in laryngeal squamous cell carcinoma by targeting APC PLoS ONE 8 2013 e77829
20. E. Arighi, M.G. Borrello, and H. Sariola RET tyrosine kinase signaling in development and cancer Cytokine Growth Factor Rev. 16 2005 441 467